Next Generation Technology

BiVictriX and IONTAS successfully complete two antibody discovery campaigns

IONTAS, a leading clinical research organisation offering phage and next generation mammalian display antibody discovery services, has successfully identified novel human binders which target BiVictriX’s proprietary “twin cancer antigens”, as part of an ongoing collaboration with BiVictriX. These binders cover a broad range of affinities including species cross-reactivity...

Read more
This site uses cookies to provide you with a great user experience. By using our website, you accept our use of cookies.